Dépôt numérique

Serotonin and serotonin reuptake inhibitors alter placental aromatase

Hudon-Thibeault, Andrée-Anne; Lopez de los Santos, Yossef; Doucet, Nicolas ORCID logoORCID: https://orcid.org/0000-0002-1952-9380; Sanderson, J. Thomas ORCID logoORCID: https://orcid.org/0000-0002-3190-2811 et Vaillancourt, Cathy ORCID logoORCID: https://orcid.org/0000-0003-0543-6244 (2019). Serotonin and serotonin reuptake inhibitors alter placental aromatase The Journal of Steroid Biochemistry and Molecular Biology , vol. 195 , nº 105470. pp. 1-11. DOI: 10.1016/j.jsbmb.2019.105470.

Ce document n'est pas hébergé sur EspaceINRS.


Serotonin reuptake inhibitors (SRIs) are currently the main molecules prescribed to pregnant women that suffer from depression. Placental cells are exposed to SRIs via maternal blood, and we have previously shown that SRIs alter feto-placental steroidogenesis in an in vitro co-culture model. More specifically, serotonin (5-HT) regulates the estrogen biosynthetic enzyme aromatase (cytochrome P450 19; CYP19), which is disrupted by fluoxetine and its active metabolite norfluoxetine in BeWo choriocarcinoma cells. Based on molecular simulations, the present study illustrates that the SRIs fluoxetine, norfluoxetine, paroxetine, sertraline, citalopram and venlafaxine exhibit binding affinity for the active-site pocket of CYP19, suggesting potential competitive inhibition. Using BeWo cells and primary villous trophoblast cells isolated from normal term placentas, we compared the effects of the SRIs on CYP19 activity. We observed that paroxetine and sertraline induce aromatase activity in BeWo cells, while venlafaxine, fluoxetine, paroxetine and sertraline decrease aromatase activity in primary villous trophoblast. The effects of the paroxetine and sertraline in primary villous trophoblasts were observed at the lower doses tested. We also showed that 5-HT and the 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) induced CYP19 activity. An increase in phosphorylation of serine and tyrosine and a decrease in threonine phosphorylation of CYP19 was also associated with DOI treatment. Our results contribute to better understanding how 5-HT and SRIs interact with CYP19 and may affect estrogen production. Moreover, this study suggests that alteration of placental 5-HT levels due to depression and/or SRI treatment during pregnancy may be associated with disruption of placental estrogen production.

Type de document: Article
Mots-clés libres: Antidepressant; CYP19; Estrogen; Phosphorylation; Trophoblast
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 22 juill. 2021 21:39
Dernière modification: 16 févr. 2022 15:33
URI: https://espace.inrs.ca/id/eprint/11606

Gestion Actions (Identification requise)

Modifier la notice Modifier la notice